Venatorx
Manufacturing · Pennsylvania, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
74 E Swedesford Rd Ste 100, Malvern, Pen...Phone Number
(610) 644-8935Website
www.venatorx.comRevenue
$33.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About Venatorx
Founded in 2010 and located in Malvern, Pennsylvania, Venatorx Pharmaceuticals is a private pharmaceutical company that focuses on the discovery and development of novel anti-infectives to treat multi-drug-resistance bacterial infections and hard-to-treat viral infections.Explore more
Venatorx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Venatorx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Venatorx had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Venatorx
Venatorx, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Venatorx recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Venatorx launches new products
Check out if Venatorx is spiking on competitors!
Funding: Get notified immidiatlly once Venatorx has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Venatorx has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Venatorx as Masked Content
Find 2 more new buyers
Compare Similar Companies to Venatorx
Compare insights from companies similar to Venatorx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Venatorx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Venatorx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Venatorx.
Venatorx financials insights
Gather financial insights about Venatorx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series A
$3.5M
2017
Series B
$42M
Unspecified
$9.4M
Venatorx Tech Stack
A closer look at the technologies used by Venatorx
See more technologies
Most Recent Scoops
Project
Venatorx is considering the purchase of solutions related to customer loyalty management such as CrowdTwist.
Spending/Investment, Customer Engagement, Relationship Marketing, Customer Retention & Development
Funding
Project
Spending/Investment, Funding
Left Company
Executive Move
Executive Moves, Left Company
Funding
Project
Award, Spending/Investment, Search, Medical Research
Open Position
Venatorx News & Media
Venatorx Pharmaceuticals Announces Changes to Executive Leadership
MALVERN, Pa.--(BUSINESS WIRE)--Venatorx Pharmaceuticals, a private, pre-commercial pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections, announced today several changes to its executive leadership team. Manos Perros, PhD, has been appointed to the Board of Directors as Executive Chairman. Dr. Perros is a distinguished pharmaceutical and biotech executive with an impressive track record that inclVenatorx Pharmaceuticals Expands Senior Leadership Team
MALVERN, Pa.--(BUSINESS WIRE)--Venatorx Pharmaceuticals, a private, pre-commercial pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections, announced expansion of its leadership team with three key industry veterans: Jason Burdette joining as Senior Vice President, CMC and Technical Operations: Armand Girard as Chief Business Officer; and Tamra Adams, and Chief Financial Officer. These appointmentsVenatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam
MALVERN, Pa. & PARSIPPANY, N.J.--(BUSINESS WIRE)--Venatorx Pharmaceuticals (Venatorx) and Melinta Therapeutics (Melinta) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for cefepime-taniborbactam, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination antibiotic under review as a potential treatment for adult patients with complicated urinary tract infections (cUTI), including acute pyelonephrNew England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection
MALVERN, Pa. & PARSIPPANY, N.J. & FLORENCE, Italy--(BUSINESS WIRE)--Venatorx Pharmaceuticals, Melinta Therapeutics LLC (“Melinta”), and Menarini Group today announced that The New England Journal of Medicine (NEJM) published the results of the CERTAIN-1 Phase 3 clinical study of the investigational agent cefepime-taniborbactam for the treatment of adult patients with complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), including those with bacteremia. The results showed th
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Venatorx
Sign Up For FreeTo access detailed company insights
Founded in 2010 and located in Malvern, Pennsylvania, Venatorx Pharmaceuticals is a private pharmaceutical company that focuses on the discovery and development of novel anti-infectives to treat multi-drug-resistance bacterial infections and hard-to-treat viral infections.... Read More
